You searched for "Ocular"

1854 results found

Exploiting nature’s randomised trials of eye disease

Confounding and reverse causation in observational ophthalmic epidemiology Traditional observational studies are inherently limited in establishing a causal effect of an exposure on an outcome of interest. One fundamental limitation is confounding, whereby causation is incorrectly attributed to a third...

My Top Five: Ophthalmology learning tools for doctors

Starting a career in ophthalmology can be both exciting and demanding. Despite its captivating and broad nature, ophthalmology often proves challenging for beginners around the globe due to limited exposure during medical school [1–5]. Fortunately, plenty of resources are available,...

My Top Five: Ophthalmology learning tools for doctors

Starting a career in ophthalmology can be both exciting and demanding. Despite its captivating and broad nature, ophthalmology often proves challenging for beginners around the globe due to limited exposure during medical school [1–5]. Fortunately, plenty of resources are available,...

The interpretation and use of ultrasound biomicroscopy (part 1)

Ultrasound Biomicroscopy (UBM) has become increasingly important for the diagnosis of a variety of anterior segment pathologies. Most ophthalmologists are familiar with conventional B-scan ultrasonography techniques, which operate at lower sound frequencies (7.5 to 20MHz). UBM is an ultrasound technique...

Epiretinal membranes in uveitic macular oedema

Epiretinal membrane (ERM) formation in uveitic macular oedema is a fairly common structural complication of the retina. The authors describe a retrospective case series of 104 eyes of 77 patients with uveitic macular oedema from a tertiary centre. The treatment...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Time is vision in central retinal artery occlusion

Central retinal artery occlusion (CRAO) is a rare but devastating vascular episode that can have severe impact on vision. Treatment is very time-limited and needs to be initiated very quickly to salvage any vision. The majority of patients present to...

Glaucoma diagnosis with spectral-domain OCT of GCL and IPL

This is a prospective, cross-sectional, observational study by the New York Eye and Ear Infirmary, which recruited normal subjects and glaucoma patients with a range of visual field loss representing various degrees of glaucomatous optic neuropathy. A total of 69...

Wet AMD outcomes post cataract surgery

The authors present the findings of a retrospective study looking at the progression of wet age-related macular degeneration (AMD) in patients who underwent cataract surgery. They recruited a series of 111 patients of which 38 were men and 73 were...

Progression of macular atrophy on long-term anti-VEGF therapy for AMD

This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...